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Abstract 
Background:  
Studying microRNA networks during heart development is essential to obtain a better understanding 
of developmental defects and diseases associated with the heart and to identify novel opportunities 
for therapeutics. Here we highlight the advantages of chicken embryos as a vertebrate model for 
studying intermediate processes of heart development. Avians develop a four-chambered heart 
closely resembling human anatomy and they develop ex utero, which makes them easily accessible. 
Furthermore, embryos are available all year with a steady supply.  
Results:  
In this report we established a novel method for the knockdown of microRNA function by 
microinjecting AntagomiRs into the chicken heart in ovo. Our approach enables the targeted delivery 
of antagomirs into a locally restricted area and is not impacted by circulation. After further embryo 
development the successful miRNA knockdown was confirmed. Loss of function phenotypes can be 
evaluated rapidly, compared to more time-consuming genetic ablation experiments. The local 
application avoids potential systemic effects of microRNA knockdown, therefore allowing the 
assessment of impacts on heart development only.  The method can be adjusted for different stages 
of chicken embryos (HH13-HH18) as well as for knockdown or targeted overexpression of coding 
genes. 
Conclusion:  
In conclusion our method allows targeted and locally restricted delivery of Antagomirs to the heart 
leading to successful knockdown of microRNA function. This method enables rapid phenotypic 
assessment, for example by gene expression analysis of multiple cardiac genes.  
Keywords: chicken embryo, micromanipulation, microinjection, heart development, microRNA, 
antagomiR 
Introduction 
The study of heart development contributed important insights into the normal process of organ 
patterning and growth control but also revealed factors involved in pathological development 
leading to a better understanding of congenital heart disease. MicroRNAs are small non-coding RNA 
molecules of approximately 23 base pairs in size that regulate gene expression (Bartel, 2009). It has 
been demonstrated previously that they play a significant role in both cardiac development and 
disease (Chen and Wang, 2012; Liu and Olson, 2010), however the details of how individual 
microRNAs regulate gene networks remain to be elucidated. Thus, further work is needed to acquire 
new insights and to potentially translate this knowledge into new avenues for medical care. Cardiac 
microRNA networks have been studied in a number of model organisms each of them with different 
advantages for analysis. Two models closely resembling human heart anatomy, with a four-
chambered heart comprising two atria and two ventricles, are the mouse (Mus musculus) and the 
chicken (Gallus gallus). The fact that mice develop in utero whereas chicken embryos develop in ovo 
has a strong impact on accessibility and therefore applicable methods. Commonly used approaches 
for altering gene expression in mice include Cre-mediated tissue specific (conditional) recombination 
of a selected target gene, CRISPR-mediated genome editing, or transgenic overexpression of genes 
of interest, allowing for permanent and/or inducible genetic alterations (Bouabe and Okkenhaug, 
2013; Singh et al., 2015). Furthermore, lineage tracing experiments that reveal cell relationships 
have been used extensively in mice by applying genetic labelling methods (Kalhor et al., 2018; Kraus 
et al., 2014). In chicken, tissue grafting, electroporation and microinjections are the most commonly 
used techniques. The embryo is highly accessible in ovo and allows stage-specific manipulations with 
subsequent read out (Bellairs and Osmond, 2014; Stern, 2005). Even though a different subset of 
techniques is used in chicken embryos lineage tracing has also been employed to study cell fate 
(Kretzschmar and Watt, 2012), for example the contributions of cardiac neural crest to outflow tract 
septation and of the second heart field to the right ventricle were first identified in the chicken 
(Wittig and Münsterberg, 2016). 
Genetic approaches in mice have significantly increased our understanding of heart development, 
however, these are time-consuming and their spatio-temporal control is limited by the ability to 
control the activity of the Cre recombinase, thus making the study of specific events during heart 
development more challenging. The precise local administration of pharmacological agents to the 
mouse heart is difficult due to in utero development and therefore lack of access to the embryonic 
heart.  Injections into the vasculature lead to systemic delivery and thus an impact on tissues other 
than the heart cannot be excluded (Goehringer et al., 2009; Krutzfeldt et al., 2005). In chicken, the 
effective delivery of viral based expression constructs needs high concentrations (Lambeth et al., 
2014), leading to potential DNA toxicity effects. A general complication is that due to heart 
contractions, injected compounds are quickly washed out into circulation (Davidson et al., 2001). 
Virus based transduction is slightly less affected by this since the virus binds to cell surface receptors. 
Effective binding can be improved by slowing the heart temporarily through embryo cooling. 
However, nucleic acid-based constructs or synthetic compounds can quickly disperse and their 
successful delivery and uptake requires steady local administration and/or temporary heart arrest, 
which could have non-specific effects on development.  
For our study we chose the chicken embryo as model organism, its developmental stages are well-
defined (Hamburger and Hamilton, 1951) and the heart is readily accessible, particularly the early 
and intermediate stages, which closely resemble human anatomy (Wittig and Münsterberg, 2016). 
Embryos are cheap to obtain and are incubated to the desired stage in controlled conditions. This 
facilitates in ovo manipulations with precise temporal and site-specific targeting and permits the 
study of different phases of intermediate heart development, including S-shape (heart) looping, 
chamber remodelling, trabeculation and septa formation. Following manipulation and further 
embryo development subsequent visual assessment and gene expression analysis is possible and 
does not require sacrificing the parent animal. Therefore, the use of chicken embryos complements 
the analysis of genetically modified embryos of other model species (Bellairs and Osmond, 2014). 
The injection technique into the chicken heart illustrated here can be applied to different 
subsections of the heart and thus overcomes some of the above-mentioned drawbacks. 
Furthermore, the targeted injections could be performed with plasmid constructs – combined with 
Lipofectamin (England et al., 2017), or with virus particles, synthetic compounds, antisense 
morpholinos or microRNA mimics and inhibitors. Delivery of microRNA inhibitors, AntagomiRs, is the 
primary focus of this report as it represents a new tool for studying the functions of individual or 
multiple microRNAs during intermediate heart development, during which the heart tube is 
remodelled into a mature chambered heart. Once mastered, this method can be used for heart-
specific knockdown and gain-of-function studies and allows medium-throughput screening of 
multiple genes of interest. 
Results  
Protocol for cardiac injections: 
The whole procedure is shown step by step in Movie 1: Cardiac injection procedure. 
1. Incubate fertilized chicken eggs 
a. Fertilized chicken eggs are stored at 17°C for up to a week prior to incubation 
b. Eggs are incubated with the blunt end up in a humidified incubator at 37°C 
i. Depending on stage of interest the length of egg incubation has to be 
adjusted. To obtain HH15 embryos we incubated fertile eggs for 
approximately 66h (Hamburger and Hamilton, 1951) 
2. Preparation of injection setup: 
a. For 30 eggs prepare 25 ml 1:500 PBS/ Pen Strep (PS) (Gibco Life Technologies) 
solution and 25 ml PBS/PS-solution with Indian ink (Winsor & Newton) 
b. Prepare Syringes with needles 
i. 1 ml syringe with 25Gx 5/8” needle for ink injection 
ii. 1 ml syringe with 25Gx 5/8” needle for incision of the extra embryonic tissue 
(EET) 
iii. 10 ml or 2 ml syringe with 21Gx2” needle for albumen removal 
c. Forceps and tweezers for removal of the shell and outer/inner membranes 
d. Adhesive tape for egg sealing 
e. Small table-top incubator for usage during procedure 
3. Prepare injection apparatus 
a. Pull needle for microinjection (borosilicate glass capillaries 1.00 mm O.D. x 0.78 mm 
I.D.) 
b. To enable easy heart manipulation, we recommend shorter needles with a very 
sharp tip, since long flexible ones will not penetrate the heart and simply bend. 
i. Needle pull settings for Sutter Instruments P-97: P=300, Heat=ramp test 
value, Pull=150, Vel=80, Time=130. 
c. Load needle with ~1.5 µl AntagomiR at 1µM (or other) using MicroloaderTM 
(Eppendorf) and mount onto microinjector 
4. Prior to procedure spray eggs with 70% Ethanol to kill surface germs 
5. Remove single egg from incubator (Figure 1A) 
6. Crack it open at the blunt end using tweezers and remove shell pieces until embryo is easily 
accessible (Figure 1B) 
7. Using syringe (i) in a shallow angle inject ink-mix beneath the embryo for contrast and apply 
2 drops PBS/PS-solution on top using a plastic Pasteur pipette to increase elasticity of EET 
(Figure 1C) 
8. Place egg under a stereo-dissecting microscope and use syringe needle (ii) to cut open the 
vitelline membrane (Figure 1D) 
a. Cut EET around heart until it is freely accessible (Figure 1E) 
9. Perform multiple injections in areas of interest (Figure 1F) 
a. Depicted is conus, primitive ventricle and primitive atrium (Figure 1F)  
10. Remove needle and visually confirm injection (Figure 1G) 
a. Injected compound (AntagomiR) is conjugated to a fluorophore 
11. Slide the needle of the large syringe (iii) down along the inside of the egg shell and remove 
albumen until the embryo is sufficiently lowered and will not touch the sealing tape (Figure 
1H) 
a. If embryo adheres to the egg shell, flush it gently using albumen until it detaches 
b. Apply a few drops PBS/PS-solution  
12. Seal the egg using clear adhesive tape 
a. Combine two strips of tape together (parallel) and apply them to the egg. Use a third 
strip and cross the other two (perpendicular) (Figure 1I) 
13. Return the egg to an incubator immediately (for convenience this could be the desk-top 
incubator). 
Embryo survival and possible timescales of experiments 
Several parameters have an impact on survival of the injected chicken embryos. In this study we 
analysed survival of embryos, injected with AntagomiR or with a scrambled sequence, 24 hours post 
injection (hpi), 48hpi and 72hpi (Krutzfeldt et al., 2005; McGlinn et al., 2009) (representative photos, 
Figure 2A). For both the non-specific scrambled control, AntagomiR-SCR, and the specific 
AntagomiR-499-5p embryo survival declined with longer incubation periods (Figure 2B). After 24 
hours post injection around 90% of embryos had survived and developed normally, this dropped to 
40% and 35% at 48hpi and 72hpi. The almost identical survival rates observed with control and 
experimental AntagomiRs suggests that the decrease in survival is due to the manipulation itself. The 
data presented for AntagomiR-SCR represents the baseline for survival and we assume that survival 
beyond 72hpi is possible, potentially even up to hatching. In experiments where other AntagomiRs 
were injected the embryos showed a steeper decline in survival (up to 100% before 48hpi, not 
shown), suggesting a biological impact affecting survival resulting from this particular knockdown.  
Several factors during the procedure should be considered to promote embryo survival. During egg 
opening, it is vital to avoid damaging the embryonic tissue and the vasculature. Bleeding indicates 
damage and these embryos cannot be used. In addition, following the microinjection embryos can 
sometimes adhere to the egg shell and their detachment can result in damage. Incubation with 
rocking prior to injection may reduce the occurrence of adherence to the shell and it has been 
reported that agitation during incubation improves hatchability and should therefore promote 
healthier development (Randles and Romanoff, 1954). In the final step of the procedure, when 
lowering the embryo after injection, it is essential to avoid contact with sealing tape. To avoid these 
confounding issues, we have excluded egg shell adhering embryos in our survival analysis.  
To make the heart accessible for injection the vitelline membrane and some of the EET surrounding 
the heart need to be partially removed. During this, caution is necessary to avoid wounding vessels 
or the heart to prevent bleeding. The same applies to the actual injection step, since the injection 
needle is sharp enough to cause small incisions in the heart. Finally, the procedure was optimized by 
returning the embryos to a heated incubator at 37°C immediately after injection, this improved 
survival rates. 
To determine if the injection procedure had an impact on heart function, we analysed heart rates 
(HR) of control-injected embryos compared to wildtype (non-manipulated) embryos as a 
representative variable for cardiac health (Figure 2C top panel). The data revealed no significant 
differences between the two groups for the first two timepoints analysed, 24hpi and 48hpi 
(unpaired t-test, p>0.05). This also shows that the injected AntagomiR has no non-specific toxicity. 
The HR becomes faster with increasing age, therefore, to ensure accurate comparison, the same 
stages of embryo development were used (Figure 2C bottom panel). The quantification of HR 
requires the heart to be visually accessible and this makes analysis of older embryos (>5 days) 
difficult. After 5 days of development the allantois is covering the heart and this made HR-
quantification challenging even though still possible for some embryos (Spurlin and Lwigale, 2013). 
However, electrophysiological methods for HR- quantification may still be suitable (Shi et al., 2013). 
We have also found that injection of some AntagomiRs can induce HR changes and the complete 
analysis of such phenotypes require detailed follow-up analysis. 
Validation of AntagomiR administration 
The injected compounds in this study were AntagomiRs, complementary sequences to microRNAs 
designed to inhibit their function (Krutzfeldt et al., 2005; McGlinn et al., 2009). The AntagomiRs 
contained two modifications, a 3’ cholesterol group to allow cell uptake and a 5’ Fluorescein group 
for tracing purposes. The Fluorescein enables easy localization of AntagomiRs during the procedure, 
which is helpful for targeting and to avoid injection into the bloodstream, potentially causing 
systemic rather than heart specific effects. Furthermore, the fluorescent tag enables detection post-
injection at 24hpi and 48hpi (Figure 3A). However, fluorescence intensity decreased over time and 
was no longer detectable at 72hpi. Signal strength may also depend on local retention of the 
AntagomiR. The AntagomiR-SCR used as a control in this study has no binding partner in the chicken 
embryo, we found that its signal intensity was reduced, compared to an AntagomiR that is directed 
against a microRNA expressed in the heart, such as miR-499-5p (Figure 3Bi) (van Rooij et al., 2009). 
After Antagomir-499-5p injection a much stronger signal was consistently detected using enzyme 
catalysed immunohistochemistry (IHC) against the FITC-tag. We propose that this is most likely due 
to binding of the endogenous complementary microRNA, miR-499-5p. In addition to IHC on 
dissected hearts (Figure 3Bi), we examined whole embryos to confirm specific targeting of the heart 
only (Figure 3Bii).  Specific staining was restricted to the heart shown by two purple stripes. Some 
faint staining was visible in the body due to trapping, which is a commonly observed drawback of 
methods involving chromophore conversion (Antin et al., 2007; Lufkin, 2007). However, if this 
diffuse signal is due to leakage of AntagomiR into other tissues, it would indicate that there was very 
little if any.  
In mice, AntagomiRs were detected for up to three weeks after systemic injection (Krutzfeldt et al., 
2005). Consistent with this, IHC against Fluorescein detected AntagomiRs for periods longer than 
48hpi (Figure 3B).  
Furthermore, Knockdown of miR-499-5p can be confirmed by Northern-Blot (Figure 3C, Supplement 
1) and qPCR (Figure 3D). Hearts were dissected post incubation, pooled (six for 24hpi & three for 
48hpi) and RNA was extracted. Both methods show a significant reduction of miR-499-5p expression 
at both timepoints, indicating that AntagomiRs are effective and stable in an in vivo environment 
(unpaired t-test, Northern Blot, n=3, 24hpi and 48hpi p<0.01, qPCR, n=5, 24hpi and 48hpi p<0.001). 
The miR-499-5p bands on Northern Blots were normalised to U6 and qPCR data was normalised to 
the expression of other microRNAs, miR-451 and miR-126-3p. These microRNAs were not targeted 
and showed stable expression. We have found that detection of U6 by qPCR was inconsistent, 
especially when using different RNA amounts for cDNA synthesis. 
In addition, we found that the molecular verification using Northern Blot and qPCR is dependent on 
the chosen RNA extraction method. If the extraction method included Trizol, a frequently used 
solution, the knockdown could not be demonstrated (Supplement 2A, B). Initially we wondered 
whether the lack of observable knockdown could be explained by a feedback mechanism, involving 
the upregulation of miR-499-5p synthesis, however qPCR detection of the longer precursor 
microRNA in Trizol extracted samples did not support this idea (Supplement 2C). Another 
explanation might be, that Trizol releases the stable duplex of AntagomiR and microRNA and thus, 
more microRNA can be detected in these samples even though microRNA function is still inhibited. 
Furthermore, Trizol has a known bias regarding GC-content, particularly when extracting microRNAs 
(Kim et al., 2012). Taking this into consideration, we do not recommend extraction methods that 
involve Trizol when examining microRNAs.  
Discussion 
In conclusion, our method can be used for AntagomiR injections and to achieve successful 
knockdown of microRNA function in the heart. The injected compound can easily be replaced and 
thus the technique is also suitable for delivery of morpholinos, or plasmid constructs, or viral 
particles to achieve transient knockdown or area specific expression of genes of interest. For 
example, in preliminary experiments injection of LNA modified microRNA mimics, usually used for 
tissue culture experiments to promote miRNA mediated silencing, showed target RNA expression 
changes (data not shown). Also, it is possible to combine multiple AntagomiRs into a single injection 
to study synergistic, antagonistic or additive effects of microRNA inhibition. The method can be 
applied to variety of stages of chicken development and thus allows the study of different processes 
of heart development. Most suitable are HH13 to HH18, after turning of the chicken embryo and 
before the heart encapsulating tissue becomes too rigid for dissection to gain access (Martinsen, 
2005; Wittig and Münsterberg, 2016). Injections at older developmental stages will allow the specific 
targeting of only the atria or ventricles, similarly at younger stages it is possible to restrict injections 
to parts of the primitive heart tube. Strikingly, following delivery the administered AntagomiR was 
locally restricted to the heart (Figure 1F and Figure 3A, B) and not affected by the circulating 
bloodstream. Therefore, this procedure allows studying the impact of microRNA-inhibition on the 
heart only, which presents an important advantage to approaches used previously (Davidson et al., 
2001; Goehringer et al., 2009). This spatial restriction is helpful to avoid effects on other organs 
caused by systemic microRNA knockdown and will improve the analysis of phenotypes. 
The method allows the downstream analysis of different parameters to assess the phenotype, 
including morphology, histology, gene expression changes and changes in physiology. Here, we 
quantified the heart rate of injected embryos and compared it to wildtype siblings. Quantification of 
zebrafish heart rates has been done using a high frame rate camera (Musso et al., 2014), this was 
adopted for this study. Video recordings of the heart allow automated heart rate quantification 
using Fiji software and furthermore allow calculation of input and output volumes. The latter 
requires visual access to both, atria and ventricles (Musso et al., 2014), which is rarely the case past 
48hpi since at that stage the embryo is covered by the allantois (Spurlin and Lwigale, 2013). 
However, by selecting recorded videos where all heart chambers are fully visible, it is possible to 
determine cardiac input and output volumes. Alternatively, the heart rate can be determined with 
electrodes producing an electrocardiogram as shown by Shi et al. (2013) in the chicken embryo. 
Electrophysiological experiments surrounding the conduction system of the heart could involve 
patch clamp, pulse wave, action potential and/or ECG measurements (Borghetti et al., 2018; Shi et 
al., 2013). Morphological changes in the heart post-injection can be analysed by serial sectioning and 
3D reconstruction (Wang et al., 2015), optical projection tomography (Sharpe et al., 2002) or 
histological staining procedures (Alturkistani et al., 2015).  
To assess successful administration and resulting knockdown of miR499-5p, we employed Northern 
Blot analysis and quantitative RT-PCR. Such analysis can be further expanded for genes of interest to 
determine differential expression and thus dissect pathways relevant for the targeted microRNA. In 
order to understand the functional relevance of miRNAs and their corresponding targets and to 
decipher the miRNA network in heart development, the samples can be further processed for 
RNAseq to obtain a broader picture of differentially expressed genes. We showed that the RNA 
extraction method used, column-based or Trizol based, affects the ability to verify the knockdown. 
The reasons for this are still unclear, but we feel that it is an important observation to report. For 
further molecular analyses, non-Trizol extracted samples are preferable. This extraction method 
enables confirmation of microRNA knockdown after AntagomiR administration (Fig. 3C, D)(Krutzfeldt 
et al., 2005; Velu and Grimes, 2012) and avoids the reported GC-bias of Trizol for microRNAs (Kim et 
al., 2012).  
Taken together the cardiac injection method presented here facilitates investigation of microRNA 
functions during intermediate heart development in the chicken embryo. Advantages of this 
knockdown approach are the targeted local delivery at specific stages of development and the short 
timeframe in which results can be obtained.  
Material and Methods 
AntagomiR design 
AntagomiRs are fully complementary to the microRNA of interest and include a 5’ Fluorescein and 3’ 
Cholesterol addition. Further the backbone consists of 2-O-methyl RNA and contains 
phosphorothioate bonds at the three most 3’ and two most 5’ bases (McGlinn et al., 2009). 
Table 1: AntagomiRs used in this study 
AntagomiR name sequence 
AntagomiR-SCR 5’-(FL)mC(*)mA(*)mUmCmCmAmUmCmAmCmUmCmAmCmUmCm 
CmAmU(*)mC(*)mA(*)mU(3'-Chl)-3’ 
AntagomiR-499-5p 5’-(FL)mC(*)mU(*)mAmAmAmCmAmUmCmAmCmUmAmCmAmAm 
GmUmCmU(*)mU(*)mA(*)mA(3’-Chl)-3’ 
Embryos 
Fertilized Dekalb White chicken eggs (Henry Stewart & Co.Ltd, Fakenham, UK ) were incubated at 
37°C until needed. Stage HH14-16 embryos (~66h) were used for the cardiac injection procedure 
(Hamburger and Hamilton, 1951). 
Fluorescence microscopy 
AnatagomiR delivery was confirmed using a LEICA MZ16F microscope with a LEICA DFC 300FX 
camera to track the fluorescence of the Fluorescein tag. Brightfield and green channel images were 
taken and merged in Adobe Photoshop CC. 
Heart Rate Assessment 
To asses heart rates, a single injected egg was removed from the incubator and a circular opening 
was cut in the tape seal. The egg was immediately placed under the microscope and a 15-30 sec clip 
at 1080p/120fps was recorded (RIBCAGE H5PRO). Subsequently the embryo was dissected and 
processed for other methods. Collected video clips were played in slow motion using Apple 
QuickTime and heart beats were counted manually by J.G.W. and M.R.G. Beats per minute were 
calculated accordingly     
      
          
    . 
Immunohistochemistry 
Endogenous phosphatases of dissected hearts have been inactivated at 67°C in HYB buffer 
overnight. Following several washes according to previously described procedures (Goljanek-Whysall 
et al., 2011) an antibody against Fluorescein (Anti-Fluorescein-AP, Fab fragments, Roche) was 
applied and incubated overnight. Again, following several washes colour was developed for all 
samples simultaneously using BCIP/NBT 
RNA extraction and RT-qPCR 
RNA and miRNA isolation from pools of dissected hearts was performed using Quick-RNA™ MiniPrep 
Plus (Zymo Research) according to the manufacturer’s protocols. We used RNA Clean & 
Concentrator™-5 (Zymo Research) in the case of Trizol Reagent (Invitrogen™) treated samples. cDNA 
was synthesized from 200 ng RNA in a 20 µl reaction using a Maxima First Strand cDNA synthesis kit 
(Thermo Fisher Scientific). For miRNAs, cDNA was synthesized from 10 ng in a 10 µl reaction using 
miRCURY LNA RT Kit (Qiagen). RT-qPCR was performed on a 7500 Real-Time PCR System (Applied 
Biosystems) using SYBR Green PCR Master Mix (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. MicroRNA specific primers have been designed by Qiagen (mir-449-5p: 
YP02111236, mir-451: YP02110557, mir-126-3p: YP02111065). Primers used for the miR-499 
precursor are F: 5’-TTTGAGGGAGCGGCAGTTAA-3’ and R: 5’-TGAGGAGAGAAGTAGCACAGACT-3’ 
(Sigma-Aldrich). RT-qPCR was normalized to β-Actin for mRNA, and miR-451 and miR-126-3p for 
micro RNA. Analysis was done according Livak and Schmittgen (2001) and significance was 
determined by unpaired t-test using GraphPad Prism. 
Northern blot 
Northern blot analysis was performed as previously described (Pall and Hamilton, 2008). Briefly, 10 
μg of total RNA was resolved on a 15% denaturing urea polyacrylamide gel. The RNA was transferred 
to a Hybond-NX nylon membrane (GE Healthcare) by semidry-blotting for 1h at 20 V and chemically 
crosslinked using 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (Sigma Aldrich) at 60°C for 2h.  
For Northern blot hybridization the membranes were pre-hybridized using Perfect Hyb buffer (Sigma 
Aldrich) and the antisense DNA oligonucleotides (Sigma-Aldrich) were end-labelled using 3000 
Ci/mmol of [γ-32P]-ATP (Perkin Elmer). The hybridization of the membranes with the 5’-32P labelled 
DNA oligonucleotide was performed overnight at 37°C. The membranes were washed twice with 
0.2x SSC and 0.1% SDS for 20 min and exposed to a phosphor imager screen for autoradiography. 
The membrane was imaged using the Typhoon Scanner and band intensities were quantified with 
the Image Quant Software (GE Healthcare).  
For re-probing of the membranes with the loading control U6 the membranes were stripped with 
0.1% SDS for 5h at 80°C.  
Antisense DNA oligonucleotide probe sequences used were: 
The miR499-5p miRCURY LNA miRNA detection (Qiagen) probe was used for the detection of miRNA 
499-5p (5’-CTAAACATCACTACAAGTCTTA-3’) and the membrane was re-probed with U6 snRNA as a 
loading control (5’-GCTAATCTTCTCTGTATCGTTCC-3’). 
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Movie 1: Cardiac injection procedure 
The movie shows all necessary details for carrying out the cardiac injection procedure described in this study. 
Figure 1: Injection Sequence. Image sequence of procedure steps. (A) Incubated egg for manipulation, (B) egg was cracked 
open and outer and inner membrane were removed, (C) ink was applied into the yolk sac below the embryo to provide 
contrast, (D) vitelline membrane and EET were cut open to access the heart, (E) accessible heart for injection, red blood 
cells are visible in the lumen, (F) injected heart along conus (C) downwards to primitive ventricle (PV) and on the right side 
the primitive atrium (PA), (G) injection verification, (H) removal of albumen and lowering of embryo, (I) sealing of egg and 
returning to incubation at 37°C. 
Figure 2: Representative results – embryo survival & impact on heart rate. Embryos survive until at least 72hpi and show 
no differences in cardiac health. (A) Representative photos of embryos post injection at the 3 time points analysed. (B) 
Survival analysis for embryos injected with AntagomiR-SCR (control) and AntagomiR-499-5p, a specific microRNA inhibitor. 
(C) Comparison of WT non-manipulated embryos vs control-injected embryos show no significant difference in heart rate. 
The bottom panel shows the distribution of HH stages that were analysed. We ensured the same proportion of HH19 and 
HH20 embryos were examined on day 4 (light blue and light red columns) and the same proportion of HH23, HH24 and 
HH25 embryos were examined on day 5 (dark blue and dark red columns). (N in (B) is number of experiments, each 
experiment comprised between 25 and 30 embryos, N in (C) represents the number of analysed hearts) 
Figure 3: Confirmation of successful AntagomiR delivery. Visual and molecular verification of AntagomiR delivery and 
microRNA knockdown. (A) Tracing of FITC-tag fluorescence of AntagomiR-SCR and AntagomiR-499-5p at 24hpi and 48hpi. 
(B) Chromophoric detection of the FITC-tag by IHC. (Bi) AntagomiR-SCR and AntagomiR-499-5p are detected by IHC at 
24hpi, 48hpi and 72hpi in dissected hearts. (Bii) Whole embryo IHC for AntagomiR-499-5p. Specific signal is detected in the 
heart (white arrowheads), faint background staining originates from trapping. (C) Northern Blot confirmation of miR-499-
5p knockdown (unpaired t-test, n=3, 24hpi and 48hpi, p<0.01). (D) qPCR confirmation of miR-499-5p knockdown (unpaired 
t-test, n=5, 24hpi and 48hpi p<0.001). 
Supplement 1: Extended Data Figure 3. Corresponding Northern Blot Images to Figure 3C three most left lanes AntagomiR-
SCR injected samples and three most right lanes Antagomir-499-5p injected samples (3 lanes) (arrow indicates target). 
Supplement 2: Difference in Results using Trizol based RNA extraction. MicroRNA-499-5p knockdown cannot be 
confirmed using RNA extraction involving Trizol. (A) Northern Blot analysis (n=3) shows a significant increase of mircoRNA-
499-5p at 24hpi but no significant difference at 48hpi (unpaired t-test, p<0.01; p>0.05) (A2) Northern Blot raw images, 
three most left lanes AntagomiR-SCR injected samples and three most right lanes Antagomir-499-5p injected samples 
(arrow indicates target) (B) qPCR analysis confirms Northern blot results (unpaired t-test, 24hpi p<0.05, 48hpi p>0.05, n=4) 
(C) qPCR quantification of mir-499-5p precursor transcript shows significant reduction at 24hpi but not 48hpi (unpaired t-
test, p<0.01; p>0.05, n=4). 
 
 
 
 
 
  
Highlights 
 
 Cardiac injections into live embryos facilitates the targeted and localized delivery of 
AntagomiRs 
 Chick embryos enable rapid phenotype analysis 
 Following AntagomiR injection the successful knockdown of the cognate microRNA was 
observed 
 The choice of RNA extraction method is critical 
 
 
 
 
